Characteristics of the corpus callosum in chronic schizophrenia treated with clozapine or risperidone and those never-treated

Table 3 Corpus callosum fractional anisotropy (FA) values in CT-SCZ, RT-SCZ, NT-SCZ and HCs

Corpus callosum	CT-SCZ, N = 23 Mean ± SD	RT-SCZ, N = 19 Mean ± SD	NT-SCZ, N = 23 Mean ± SD	HCs, N = 35 Mean ± SD	F value	p value	Post-hoc analyses
Corpus callosum	CT-SCZ, N = 23 Mean ± SD	RT-SCZ, N = 19 Mean ± SD	NT-SCZ, N = 23 Mean ± SD	HCs, N = 35 Mean ± SD	F value	p value	NT-SCZ vs. HCs	NT-SCZ vs. RT-SCZ	NT-SCZ vs. CT- SCZ	RT-SCZ vs. CT- SCZ	RT-SCZ vs. HCs	CT-SCZ vs. HCs
Anterior	0.54 ± 0.04	0.57 ± 0.05	0.50 ± 0.06	0.55 ± 0.04	4.761	0.004	0.001**	0.008**	0.023*	NS	NS	NS
Mid-anterior	0.43 ± 0.06	0.42 ± 0.04	0.43 ± 0.05	0.42 ± 0.04	0.530	0.663	NS	NS	NS	NS	NS	NS
Central	0.45 ± 0.08	0.45 ± 0.06	0.47 ± 0.05	0.47 ± 0.06	0.342	0.759	NS	NS	NS	NS	NS	NS
Mid-posterior	0.41 ± 0.07	0.42 ± 0.07	0.42 ± 0.06	0.41 ± 0.04	1.016	0.389	NS	NS	NS	NS	NS	NS
Posterior	0.60 ± 0.05	0.64 ± 0.06	0.63 ± 0.06	0.63 ± 0.04	0.972	0.409	NS	NS	NS	NS	NS	NS

Note: CT-SCZ clozapine-treated schizophrenia patients, RT-SCZ risperidone-treated schizophrenia patients, NT-SCZ never-treated schizophrenia patients, HCs healthy controls, NS not significant, *, Significant group difference at P < 0.05; **, P < 0.01; ***, P < 0.001

ISSN: 1471-244X